JP5835729B2 - 筋萎縮性側索硬化症の予防および治療用医薬組成物 - Google Patents

筋萎縮性側索硬化症の予防および治療用医薬組成物 Download PDF

Info

Publication number
JP5835729B2
JP5835729B2 JP2011191990A JP2011191990A JP5835729B2 JP 5835729 B2 JP5835729 B2 JP 5835729B2 JP 2011191990 A JP2011191990 A JP 2011191990A JP 2011191990 A JP2011191990 A JP 2011191990A JP 5835729 B2 JP5835729 B2 JP 5835729B2
Authority
JP
Japan
Prior art keywords
group
tert
sec
butoxycarbonyl
butylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011191990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012051888A5 (enExample
JP2012051888A (ja
Inventor
治久 井上
治久 井上
志保 北岡
志保 北岡
香代子 月田
香代子 月田
高橋　良輔
良輔 高橋
村上　学
学 村上
憲夫 中辻
憲夫 中辻
志成 上杉
志成 上杉
康行 淺井
康行 淺井
裕地 天貝
裕地 天貝
一博 饗庭
一博 饗庭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STEM CELL AND DRUG DISCOVERY INSTITUTE
ReproCELL Inc
Kyoto University
Original Assignee
STEM CELL AND DRUG DISCOVERY INSTITUTE
ReproCELL Inc
Kyoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STEM CELL AND DRUG DISCOVERY INSTITUTE, ReproCELL Inc, Kyoto University filed Critical STEM CELL AND DRUG DISCOVERY INSTITUTE
Publication of JP2012051888A publication Critical patent/JP2012051888A/ja
Publication of JP2012051888A5 publication Critical patent/JP2012051888A5/ja
Application granted granted Critical
Publication of JP5835729B2 publication Critical patent/JP5835729B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011191990A 2010-09-02 2011-09-02 筋萎縮性側索硬化症の予防および治療用医薬組成物 Expired - Fee Related JP5835729B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37955810P 2010-09-02 2010-09-02
US61/379,558 2010-09-02

Publications (3)

Publication Number Publication Date
JP2012051888A JP2012051888A (ja) 2012-03-15
JP2012051888A5 JP2012051888A5 (enExample) 2014-10-16
JP5835729B2 true JP5835729B2 (ja) 2015-12-24

Family

ID=45773059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011191990A Expired - Fee Related JP5835729B2 (ja) 2010-09-02 2011-09-02 筋萎縮性側索硬化症の予防および治療用医薬組成物

Country Status (4)

Country Link
US (1) US9856210B2 (enExample)
EP (1) EP2611437B1 (enExample)
JP (1) JP5835729B2 (enExample)
WO (1) WO2012029994A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507829SA (en) 2013-03-21 2015-12-30 Univ Kyoto Pluripotent stem cell for neuronal differentiation induction
CN104045598B (zh) * 2014-05-29 2017-02-15 烟台大学 一种含芳胺结构的硫脲类化合物及其制备方法和应用
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
EP3246046A4 (en) * 2015-01-13 2018-12-05 Kyoto University Agent for preventing and/or treating amyotrophic lateral sclerosis
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
EP4046688B1 (en) 2019-10-18 2025-04-09 Takeda Pharmaceutical Company Limited Heterocyclic compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US8227643B2 (en) 2002-05-31 2012-07-24 Proteotech, Inc. Sirtuin 1 and the treatment of neurodegenerative diseases
AU2005225559A1 (en) 2004-03-29 2005-10-06 Neurosearch A/S Novel urea derivatives and their medical use
JP5704785B2 (ja) * 2004-07-19 2015-04-22 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫抑制のためのｆｌｔ３阻害剤
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
GB0606429D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Organic compounds
CA2645633A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
GB0609378D0 (en) * 2006-05-11 2006-06-21 Novartis Ag Organic compounds
WO2008031835A2 (en) 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors
US20080234332A1 (en) * 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
US8093425B2 (en) * 2007-04-30 2012-01-10 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009011893A2 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
CN102159556A (zh) 2008-08-15 2011-08-17 得克萨斯大学评议会 1,4-苯并嗪化合物及其衍生物作为治疗药物用于治疗神经变性病状

Also Published As

Publication number Publication date
EP2611437A1 (en) 2013-07-10
US9856210B2 (en) 2018-01-02
EP2611437B1 (en) 2017-03-29
EP2611437A4 (en) 2014-02-12
US20130225642A1 (en) 2013-08-29
JP2012051888A (ja) 2012-03-15
WO2012029994A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
JP2012051888A (ja) 筋萎縮性側索硬化症の予防および治療用医薬組成物
CN100553631C (zh) 4-氟-n-(1,2-二氢化茚-2-基)苯甲酰胺的制药用途
EP3677584A1 (en) Compound having bruton&#39;s tyrosine kinase (btk)-inhibition and degradation activity
JP2020152641A (ja) リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途
CN112638866A (zh) 索拉非尼衍生物的共晶体及其制备方法
JP2020520381A (ja) ピロロピリジン誘導体化合物、その製造方法及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防または治療のための薬学的組成物
TW202219038A (zh) 結晶之PPAR-δ促效劑
JP7021405B2 (ja) イソクエン酸脱水素酵素（ｉｄｈ）阻害剤
CN111556750A (zh) 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途
CN116514902A (zh) 氘代拟肽类化合物及其用途
US8530453B2 (en) Compounds and methods for the treatment of pain and other diseases
EP4142878B1 (en) Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
US9403803B2 (en) Indole-3-carboxamides as kinase inhibitors
WO2016007993A1 (en) Benzene sulfonamide-based inhibitors of sphingosine kinase
JP7360229B2 (ja) フェロトーシス阻害剤及びその用途
JP2007186435A (ja) ニコチンアミド誘導体
CA2961021C (en) Anti-endothelial lipase compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
EP2871181B1 (en) Novel Compounds for Regeneration of Terminally-Differentiated Cells and tissues
JPWO2008050600A1 (ja) 酸化ストレス性細胞死を分子背景とする難治性疾患の治療または予防剤
JP2008013446A (ja) 酸化ストレスによる細胞変性を分子背景とする難治性疾患の治療または予防剤
JP2018016572A (ja) Ｎ−ピリダジン−３−イルスルホンアミド誘導体
WO2013120896A1 (en) Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (pde4)
CN102336740B (zh) 一类咪唑类化合物及其用途
HK40050156A (en) Co-crystal of sorafenib derivatives and process for preparation thereof
JPWO2016084870A1 (ja) アシルアミノフェニル基を有する化合物及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151027

R150 Certificate of patent or registration of utility model

Ref document number: 5835729

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees